Agomab Therapeutics Nv (AGMB) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of and for the year 2025, average high and low, overall ranking from Dec 31 2025 to - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Agomab Therapeutics Nv  (NASDAQ: AGMB)


Agomab Therapeutics Nv's ROI from its fourth quarter of 2025 to the fourth quarter of and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Agomab Therapeutics Nv's ROI in the fourth quarter of 2025?
Agomab Therapeutics Nv recorded a cumulative net loss of $-70 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -46.29%.

Within the Healthcare sector Agomab Therapeutics Nv achieved the highest return on investment. While the total ranking for ROI remained the same, compared to the third quarter of 2025 at no. .

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 151 151 151 151 0
Return On Investment (TTM) -46.29 % 0 % 0 % 0 % -
AGMB's Overall Ranking # # # # #
Seq. Investment Change TTM 33.33 % 50 % 100 % - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -70 0 0 0 0

AGMB Company Profile >> Back to AGMB Roi Comparisons >> See Annual AGMB Return On Investment



Return On Investment AGMB's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 







Financial Statements
Agomab Therapeutics Nv's IV. Quarter Investments $ 151 Millions AGMB's Balance sheet
Agomab Therapeutics Nv's IV. Quarter Income $ -70 Millions Quarterly AGMB's Income Statement
AGMB's Income by Division See AGMB's Income by Division


AGMB Annual Return On Investment (Dec 31 2025)
2025



Total Investments in Millions 151 0 0 0 0
Y / Y Investment Growth - - - - -
Net Income in Millions -70 0 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -46.29 % - - - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AGMB's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AGMB's Competitors
Subscribers only: Roi for Agomab Therapeutics Nv's Suppliers
Subscribers only: Return On Investment for AGMB's Customers

Other Ratios
AGMB's Roa AGMB's Inventory Turnover Ratio AGMB's Growth Rates AGMB's Dividend Statistics
AGMB's Profitability Ratios AGMB's Asset Turnover Ratio AGMB's Dividend Growth
AGMB's Roe AGMB's Valuation Ratios AGMB's Financial Strength Ratios AGMB's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI

Date modified: 2026-04-24T15:30:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.